USANA Health Sciences Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

USANA Health SciencesDer Gewinn des Unternehmens wird voraussichtlich um 0.7% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 0.4% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich sinken um 0.5% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 8.4% betragen.

Wichtige Informationen

-0.7%

Wachstumsrate der Gewinne

-0.5%

EPS-Wachstumsrate

Personal Products Gewinnwachstum	25.5%
Wachstumsrate der Einnahmen	0.4%
Zukünftige Eigenkapitalrendite	8.4%
Analystenabdeckung	Low
Zuletzt aktualisiert	23 Oct 2024

Jüngste Aktualisierungen zum künftigen Wachstum

USANA Health Sciences, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Jul 26

USANA Health Sciences, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

May 03

Recent updates

USANA Health Sciences (NYSE:USNA) Could Be Struggling To Allocate Capital

Sep 26

Is There Now An Opportunity In USANA Health Sciences, Inc. (NYSE:USNA)?

Sep 08

USANA Health Sciences, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Jul 26

There Is A Reason USANA Health Sciences, Inc.'s (NYSE:USNA) Price Is Undemanding

Jul 17

USANA Health Sciences (NYSE:USNA) Might Be Having Difficulty Using Its Capital Effectively

May 29

USANA Health Sciences, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

May 03

Here's What's Concerning About USANA Health Sciences' (NYSE:USNA) Returns On Capital

Jul 27

USANA Earnings Preview: From China's Challenge To India's Promise

Jul 21

USANA Health Sciences says Brown will transition to CEO in July 2023

Feb 13

Returns On Capital At USANA Health Sciences (NYSE:USNA) Paint A Concerning Picture

Feb 02

USANA Health Sciences down 17% after revising 2022 outlook below consensus estimates

Oct 25

Here's What To Make Of USANA Health Sciences' (NYSE:USNA) Decelerating Rates Of Return

Oct 18

Are Investors Undervaluing USANA Health Sciences, Inc. (NYSE:USNA) By 26%?

Jul 22

Returns On Capital At USANA Health Sciences (NYSE:USNA) Have Stalled

Jul 07

Is USANA Health Sciences (NYSE:USNA) Using Too Much Debt?

Jun 14

Gewinn- und Umsatzwachstumsprognosen

NYSE:USNA - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	869	51	64	80	2
12/31/2025	844	47	59	75	2
12/31/2024	850	47	58	76	2
9/28/2024	862	54	66	81	N/A
6/29/2024	875	55	59	74	N/A
3/30/2024	900	62	60	75	N/A
12/30/2023	921	64	56	71	N/A
9/30/2023	928	60	75	85	N/A
7/1/2023	948	63	79	92	N/A
4/1/2023	974	65	86	97	N/A
12/31/2022	999	69	94	104	N/A
10/1/2022	1,038	77	78	88	N/A
7/2/2022	1,079	89	84	97	N/A
4/2/2022	1,151	108	108	121	N/A
1/1/2022	1,186	117	108	121	N/A
10/2/2021	1,230	136	133	144	N/A
7/3/2021	1,254	139	148	156	N/A
4/3/2021	1,176	129	140	149	N/A
1/2/2021	1,135	125	145	160	N/A
9/26/2020	1,095	116	149	168	N/A
6/27/2020	1,058	110	149	169	N/A
3/28/2020	1,055	103	131	152	N/A
12/28/2019	1,061	101	110	127	N/A
9/28/2019	1,089	102	97	111	N/A
6/29/2019	1,125	109	104	116	N/A
3/30/2019	1,170	121	127	138	N/A
12/29/2018	1,189	126	141	152	N/A
9/29/2018	1,163	88	154	167	N/A
6/30/2018	1,128	81	N/A	125	N/A
3/31/2018	1,084	70	N/A	141	N/A
12/30/2017	1,047	63	N/A	124	N/A
9/30/2017	1,027	90	N/A	124	N/A
7/1/2017	1,020	97	N/A	145	N/A
4/1/2017	1,021	99	N/A	125	N/A
12/31/2016	1,006	100	N/A	137	N/A
10/1/2016	986	102	N/A	119	N/A
7/2/2016	965	98	N/A	113	N/A
4/2/2016	940	97	N/A	101	N/A
1/2/2016	918	95	N/A	111	N/A
10/3/2015	914	92	N/A	112	N/A
7/4/2015	872	86	N/A	120	N/A
4/4/2015	827	80	N/A	126	N/A
1/3/2015	790	77	N/A	105	N/A
9/27/2014	749	76	N/A	102	N/A
6/28/2014	731	73	N/A	83	N/A
3/29/2014	731	78	N/A	81	N/A
12/28/2013	718	79	N/A	99	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: USNAFür die nächsten 3 Jahre wird ein Rückgang der Gewinne prognostiziert (-0.7% pro Jahr).

Ertrag vs. Markt: USNAFür die nächsten 3 Jahre wird ein Rückgang der Gewinne prognostiziert (-0.7% pro Jahr).

Hohe Wachstumserträge: USNAFür die nächsten 3 Jahre wird mit einem Rückgang der Erträge gerechnet.

Einnahmen vs. Markt: USNADie Einnahmen des Unternehmens (0.4% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8.9% pro Jahr).

Hohe Wachstumseinnahmen: USNADie Einnahmen des Unternehmens (0.4% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: USNADie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (8.4%).

USANA Health Sciences Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

USANA Health Sciences, Inc. Updates Consolidated Earnings Guidance for the Fiscal Year 2024

Consensus EPS estimates fall by 10%

USANA Health Sciences, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Price target decreased by 8.0% to US$52.00

USANA Health Sciences, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Price target decreased by 17% to US$56.50

Recent updates

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

USANA Health Sciences, Inc. Updates Consolidated Earnings Guidance for the Fiscal Year 2024

USANA Health Sciences, Inc. to Report Q3, 2024 Results on Oct 22, 2024

USANA Health Sciences (NYSE:USNA) Could Be Struggling To Allocate Capital

Is There Now An Opportunity In USANA Health Sciences, Inc. (NYSE:USNA)?

USANA Health Sciences, Inc. Launches New, Innovative Skincare and Protein Products Resurfacing Serum and Whey Protein Isolate Up the Game for USANA

Chief People Officer recently sold US$240k worth of stock

Consensus EPS estimates fall by 10%

USANA Health Sciences, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

New major risk - Revenue and earnings growth

Price target decreased by 8.0% to US$52.00

There Is A Reason USANA Health Sciences, Inc.'s (NYSE:USNA) Price Is Undemanding

USANA Health Sciences, Inc. to Report Q2, 2024 Results on Jul 23, 2024

Founder & Chairman Emeritus recently sold US$180k worth of stock

Founder & Chairman Emeritus notifies of intention to sell stock

USANA Health Sciences (NYSE:USNA) Might Be Having Difficulty Using Its Capital Effectively

Chief People Officer recently sold US$132k worth of stock

Now 22% undervalued

Chief Financial Officer recently sold US$233k worth of stock

Insider notifies of intention to sell stock

Insider recently sold US$179k worth of stock

USANA Health Sciences, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

First quarter 2024 earnings: EPS exceeds analyst expectations

Is Now The Time To Look At Buying USANA Health Sciences, Inc. (NYSE:USNA)?

USANA Health Sciences, Inc. to Report Q1, 2024 Results on Apr 30, 2024

USANA Health Sciences, Inc.'s (NYSE:USNA) Prospects Need A Boost To Lift Shares

USANA Health Sciences, Inc., Annual General Meeting, May 06, 2024

New minor risk - Insider selling

Chief Legal Officer recently sold US$232k worth of stock

Price target decreased by 17% to US$56.50

Chief Financial Officer exercised options and sold US$161k worth of stock

New major risk - Revenue and earnings growth

USANA Health Sciences (NYSE:USNA) Could Be Struggling To Allocate Capital

Full year 2023 earnings: EPS exceeds analyst expectations

USANA Health Sciences, Inc. Provides Earnings Guidance for the Fiscal Year 2024

USANA Health Sciences, Inc. to Report Q4, 2023 Results on Feb 06, 2024

Is It Too Late To Consider Buying USANA Health Sciences, Inc. (NYSE:USNA)?

Investor sentiment deteriorates as stock falls 15%

Price target increased by 8.8% to US$74.00

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

USANA Health Sciences, Inc. Revises Earnings Guidance for the Year 2023

USANA: New Digital Tools And Solid Balance Sheet Imply Undervaluation

USANA Health Sciences, Inc. to Report Q3, 2023 Results on Oct 24, 2023

Are Investors Undervaluing USANA Health Sciences, Inc. (NYSE:USNA) By 22%?

Now 21% undervalued after recent price drop

Chief People Officer recently sold US$239k worth of stock

Chief People Officer notifies of intention to sell stock

Here's What's Concerning About USANA Health Sciences' (NYSE:USNA) Returns On Capital

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

USANA Health Sciences, Inc. Updates Earnings Guidance for the Year 2023

USANA Earnings Preview: From China's Challenge To India's Promise

USANA Health Sciences, Inc. to Report Q2, 2023 Results on Jul 25, 2023

USANA Health Sciences, Inc. to Report Q2, 2023 Results on Jul 25, 2023

Price target increased by 22% to US$64.00

Insufficient new directors

Chief Sales Officer notifies of intention to sell stock

Insider recently sold US$811k worth of stock

Independent Director recently sold US$165k worth of stock

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Chairman of the Board & CEO recently sold US$319k worth of stock

Chairman of the Board & CEO notifies of intention to sell stock

Consensus EPS estimates fall by 15%

Kevin Guest to Transit to the Role of Executive Chairman of USANA Health Sciences, Inc., Effective July 1, 2023

USANA Health Sciences says Brown will transition to CEO in July 2023

Insider recently sold US$116k worth of stock

Chairman of the Board & CEO exercised options and sold US$179k worth of stock

Usana Health Sciences, Inc. Reiterates Consolidated Earnings Guidance for the Fiscal Year 2023

Returns On Capital At USANA Health Sciences (NYSE:USNA) Paint A Concerning Picture

USANA Health Sciences, Inc. to Report Q4, 2022 Results on Feb 07, 2023